The study focuses on Post Covid Syndrome, a condition that can follow a COVID‑19 infection and often includes persistent tiredness and reduced ability to carry out everyday tasks. The medication being tested is the antidepressant and smoking‑cessation drug bupropion, given in tablet form, and it is compared with an inactive tablet known as placebo.
The main aim of the trial is to find out whether bupropion can reduce the level of fatigue and improve physical functioning in people with this condition. Participants are assigned by chance to receive either the active drug or the placebo, take the study tablets for about eight weeks, and attend a few clinic visits: one at the start, one midway through treatment, one at the end of the eight‑week period, and a follow‑up about four weeks later. During these visits, simple questionnaires and short physical tests are completed.
The questionnaires include the Fatigue Severity Scale, which asks the participant to rate how often they feel exhausted during daily activities, and the Short Form-36 Physical Function, which measures how easy it is to perform common tasks such as walking or climbing stairs. Additional brief surveys evaluate mood, anxiety and breathing difficulty, while a quick sit‑to‑stand test checks basic exercise capacity. All assessments are designed to be easy to understand and complete.
Germany 